Đang chuẩn bị liên kết để tải về tài liệu:
Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: Final results of a noninterventional study

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Data are limited regarding routine use of everolimus after initial vascular endothelial growth factor (VEGF)–targeted therapy. The aim of this prospective, noninterventional, observational study was to assess efficacy and safety of everolimus after initial VEGF-targeted treatment in patients with metastatic renal cell carcinoma (mRCC) in routine clinical settings. |

TÀI LIỆU LIÊN QUAN

Chuyển đổi Everolimus ở bệnh nhân ghép thận: Kết quả bước đầu tại Bệnh viện Chợ Rẫy

Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2- negative breast cancer: A randomized pilot trial

Báo cáo y học: "Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors"

Final results from IMPROVE: A randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis

Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: Case report and literature review

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: Results of matching-adjusted indirect comparison analyses

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy

Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.